Experimental study on the co-expression of double genes AdvCD40L-IRES2-ICOSL in mouse breast cancer model

Objective: This study aims to investigate the therapeutic effect of CD40L-IRES2-ICOSL adenoviral vector on mouse breast cancer model. Materials and Methods: CD40L, ICOSL, and CD40L-IRES2-ICOSL adenoviral vectors were constructed by gene transfection technique. Eighty BALB/c mice were selected, in which animal models of mouse breast cancer were established with the human MCF7 breast cancer cell line. A total of 72 successful model in mice. Mice were randomly divided into four groups: control group, CD40L group, ICOSL group, and CD40L-IRES2-ICOSL group, with 18 mice in each group. Two weeks later, breast cancer cells transfected with empty vector and recombinant vectors were injected into the tumor body of mice. Histopathological changes, tumor volumes and changes in weight, and survival time of tumor bearing mice were observed. Results: The T infiltration of lymphocytes in tumors significantly increased in the CD40L, ICOSL, and CD40L-IRES2-ICOSL groups. Compared with the control group, tumor growth was retarded, volumes were reduced, and survival times were prolonged in tumor bearing mice in both the CD40L and ICOSL groups, and the differences between these two groups were statistically significant (p < 0.05). In particular, this difference was statistically significant in the CD40L-IRES2-ICOSL group (p < 0.01). However, there was no significant difference between the CD40L and ICOSL groups. Conclusions: In the treatment of the animal model of mice with breast cancer, the co-expression of double genes of Adv CD40LIRES2-ICOSL can inhibit tumor growth and prolong the survival time of the MCF-7 human breast cancer bearing mice.

Breast cancer; Gene therapy; AdvCD40L-IRES2-ICOSL.

[1] Bièche I., Tozlu S., Girault I., Lidereau R.: “Identification of a threegene-expression signature of poor-prognosis breast carcinoma”. Mol. Cancer, 2004, 3, 37.

[2] Wada A., Tada Y., Shimozato O., Takiguchi Y., Tatsumi K., Kuriyama T., Tagawa M.: “Expression of CD40 ligand in CD40- positivemurine tumors activates transcription of the interleukin-23 subunit genes and produces antitumor responses”. Anticancer Res., 2004, 24, 2713.

[3] Vieira P.L., Wassink L., Smith L.M., Nam S., Kingsbury G.A., Gutierrez-Ramos J.C., et al.: “ICOS-mediated signaling regulates cytokine production by human T cells and provides a unique signal to selectively control the clonal expansion of Th2 helper cells”. Eur. J. Immunol., 2004, 34, 1282.

[4] Djukanovic R.: “The role of cost imulation in airway inflammation”. Clin. Exp. Allergy, 2000, 30, 46.

[5] Watanabe M., Watanabe S., Hara Y., Harada Y., Kubo M., Tanabe K., et al.: “ICOS- mediated cost imulation on Th2 differentiation is achieved by the enhancement of IL-4 recept- ormediated signaling”. J. Immunol., 2005, 174, 1989.

[6] Aldinucci D., Gloghini A., Pinto A., Colombatti A., Carbone A.: “The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment”. Leuk. Lymphoma, 2012, 53, 195.

[7] Chatzigeorgiou A., Lyberi M., Chatzilymperis G., Nezos A., Kamper E.: “CD40/CD40L signaling and its implication in health and disease”. Biofactors, 2009, 35, 474.

[8] Santilli F., Basili S., Ferroni P., Davì G.: “CD40/CD40L system and vascular disease”. Intern. Emerg. Med., 2007, 2, 256.

[9] Wilcox R.A., Ansell S.M., Lim M.S., Zou W., Chen L.: “The B7 homologues and their receptors in hematologic malignancies”. Eur. J. Haematol., 2012, 88, 465.

[10] Yong P.F., Salzer U., Grimbacher B.: “The role of costimulation in antibody deficiencies: ICOS and common variable immunodeficiency”. Immunol. Rev., 2009, 229, 101.

[11] Simpson T.R., Quezada S.A., Allison J.P.: “Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS)”. Curr. Opin. Immunol., 2010, 22, 326.

[12] Langlands F.E., Horgan K., Dodwell D.D., Smith L.: “Breast cancer subtypes: response to radiotherapy and potential radiosensitisation”. Br. J. Radiol., 2013, 86, 20120601.

[13] Yan S., Jiao X., Zou H., Li K.: “Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases”. Diagn. Pathol., 2015, 10, 62.

[14] Huang J.T., Liu Y.J., Wang J., Xu Z.G., Yang Y., Shen F., et al.: “Next generation digital PCR measurement of hepatitis B virus copy number in formalinfixed paraffin-embedded hepatocellular carcinoma tissue”. Clin. Chem., 2015, 61, 290.

[15] Ho-Yen C.M., Green A.R., Rakha E.A., Brentnall A.R., Ellis I.O., Kermorgant S., Jones J.L.: “C-Met in invasive breast cancer:is there a relationship with the basal-like subtype?” Cancer, 2014, 120, 163.

[16] Chen W., Zhang B., Guo W., Gao L., Shi L., Li H., et al.: “miR-429 inhibits glioma invasion through BMK1 suppression”. J. Neurooncol., 2015, 125, 43.

[17] Fan C., Lin Y., Mao Y., Huang Z., Liu A.Y., Ma H., et al.: “MicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS, MTA1 and HMGA2”. Oncotarget, 2016, 7, 21825

[18] Taylor A.P., Leon E., Goldenberg D.M.: “Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement”. Br. J. Cancer, 2010, 103, 82.

[19] Shi L., Zhang B., Sun X., Lu S., Liu Z., Liu Y., et al.: “MiR-204 inhibits human NSCLC metastasis through suppression of NUAK1”. Br. J. Cancer, 2014, 111, 2316.

[20] Joseph R., Poschmann J., Sukarieh R., Too PG., Julien SG., Xu F., et al.: “ACSL1 Is Associated With Fetal Programming of Insulin Sensitivity and Cellular Lipid Content”. Mol. Endocrinol., 2015, 29, 909.

[21] Li L.O., Grevengoed T.J., Paul D.S., Ilkayeva O., Koves T.R., et al.: “Compartmentalized acyl-CoA metabolism in skeletal muscle regulates systemic glucose homeostasis”. Diabetes, 2015, 64, 23.